Feb 27, 2023
|
Ardelyx to Participate at the Cowen 43rd Annual Health Care Conference
|
Feb 23, 2023
|
Ardelyx to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 2, 2023
|
Feb 2, 2023
|
Ardelyx, Inc. Reports Employment Inducement Grants
|
Dec 29, 2022
|
FDA Grants Appeal for Ardelyx's XPHOZAH® (tenapanor)
|
Dec 23, 2022
|
Ardelyx, Inc. Reports Employment Inducement Grants
|
Dec 16, 2022
|
Ardelyx Provides Update on FDA Appeal for XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis
|
Nov 22, 2022
|
Ardelyx to Present at the 34th Annual Piper Sandler Healthcare Conference
|
Nov 16, 2022
|
Ardelyx Announces FDA Advisory Committee Votes that the Benefits of XPHOZAH® (tenapanor) Outweigh its Risks for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis
|
Nov 16, 2022
|
Ardelyx Stock Trading Halted Today; FDA Advisory Committee to Discuss XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis
|
Nov 4, 2022
|
National Kidney Foundation and Ardelyx, Inc. Survey Finds Dialysis Patients Struggle to Maintain Serum Phosphorus Levels
|